On January 5, 2026, ScinoPharm Taiwan Ltd. (TWSE: 1789), based in Tainan, announced a significant milestone: U.S. Food and Drug Administration (FDA) approval for its Glatiramer Acetate Injection, a therapeutic equivalent to Teva’s Copaxone® for the treatment of relapsing forms of multiple sclerosis (MS). This approval positions ScinoPharm as the only Taiwanese pharmaceutical company to successfully navigate the stringent regulatory pathway for this product, underscoring Taiwan’s emerging role in the global complex generics sector.
Alpha- and beta-thalassemia are inherited hemoglobinopathies causing chronic hemolytic anemia, ineffective erythropoiesis, iron overload, and complications including fatigue and organ damage. Management has relied on supportive care such as transfusions and chelation, with no prior disease-modifying oral therapies approved for all subtypes. Mitapivat, a first-in-class oral pyruvate kinase activator, targets underlying red blood cell energy deficits to improve survival and function.
On December 30, 2025, Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion in adults. This approval represents a historic milestone, as it introduces the first new pharmacologic treatment for motion sickness in over 40 years, advancing beyond traditional antihistamines and antimuscarinics like scopolamine patches, which often carry limitations such as drowsiness or limited efficacy.
Injectable GLP-1 receptor agonists like semaglutide (Wegovy® 2.4 mg weekly) have transformed obesity treatment, demonstrating substantial weight loss and cardiovascular risk reduction. However, patient preference for oral administration and potential barriers to injectable therapies highlight the need for non-injectable options. Novo Nordisk developed a once-daily oral formulation of semaglutide at 25 mg for weight management.
On December 12, 2025, the U.S. Food and Drug Administration (FDA) granted approval for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) in combination with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC). This supplemental New Drug Application (sNDA) approval marks AKEEGA as the first and only precision medicine combination of a PARP inhibitor and androgen receptor pathway inhibitor specifically indicated for BRCA2-mutated mCSPC, expanding its prior 2023 approval for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Hypertension remains a global health crisis, affecting over 1.4 billion people and serving as a leading risk factor for cardiovascular and renal diseases. Despite advances in antihypertensive therapies, approximately 50% of treated patients in the US fail to achieve blood pressure control with multiple agents, highlighting a critical unmet need in hard-to-control (uncontrolled or treatment-resistant) hypertension. Aldosterone, a hormone that promotes sodium and water retention, plays a pivotal role in this resistance, yet targeted interventions have been limited for over two decades.
